Revenue grew 3.02% to ¥20.98B and net profit rose 5.87% to ¥3.56B in 2024, with strong outpatient and surgery growth, continued expansion, and a focus on digital and international strategy. Cash dividend of ¥1.6 per 10 shares proposed.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.